Polymyositis

Related records

Broader conditions (15)

• Acquired idiopathic inflammatory myopathy
• Acquired skeletal muscle disease
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Disease by etiologic mechanism
• Human disease
• Idiopathic disease
• Idiopathic inflammatory myopathy
• Inflammatory disease
• Muscle tissue disorder
• Musculoskeletal system disorder
• Myopathy
• Myositis disease
• Skeletal muscle disorder

Narrower conditions (15)

• Adermatopathic dermatomyositis
• Adult dermatomyositis
• Amyopathic dermatomyositis
• Anti-MDA5 dermatomyositis
• Anti-Mi2 dermatomyositis
• Anti-NXP2 dermatomyositis
• Anti-SAE dermatomyositis
• Anti-TIF1 dermatomyositis
• Classical dermatomyositis
• Clinically amyopathic dermatomyositis
• Dermatomyositis
• Hypomyopathic dermatomyositis
• Juvenile dermatomyositis
• Juvenile polymyositis
• Neonatal dermatomyositis

Trials (73)

• A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
• A Clinical Trial for CTD-ILD Treatment
• A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
• A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
• A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
• A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
• A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
• A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
• A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
• Abatacept Treatment in Polymyositis and Dermatomyositis
• Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
• Add-on Intravenous Immunoglobulins in Early Myositis
• Adult and Juvenile Myositis
• Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Approved drugs (2)

• Cortisone acetate
• Prednisone

Drugs in development (26)

• Abatacept Phase 2
• Aldesleukin Phase 2
• Anakinra Phase 2
• Anifrolumab Phase 3
• Belimumab Phase 2
• Corticotropin Phase 2
• Cyclophosphamide Phase 1
• Cyclosporine Phase 2
• Daxdilimab Phase 1
• Dazukibart Phase 3
• Efgartigimod alfa Phase 2
• Enpatoran Phase 2
• Fludarabine Phase 1
• Froniglutide Phase 2
• Human immunoglobulin G Phase 2
• Infliximab Phase 2
• Methimazole Phase 2
• Methotrexate Phase 3
• Prednisolone Phase 2
• Rituximab Phase 2

Other linked drugs (1)

• Atorvastatin